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Summary.-Serum alpha-foetoprotein (AFP) and serum carcinoembryonic antigen
(CEA) levels were measured, serially whenever possible, in 70 patients attending the
Institute of Radiotherapy, Rotterdam, on account of testicular (65) or ovarian (4)
germ cell tumours or, in one case, an endodermal sinus (yolk sac) tumour in the
mediastinum. In 15 patients the disease was active; in the others it was in remission.
Patients with active disease had raised serum AFP levels which correlated well
with disease activity; no patient without evidence of active disease had raised serum
AFP levels. None of the patients with active disease was found to have raised serum
CEA levels.
There was no correlation between serum AFPand CEAlevelsinpatientswith germ
cell neoplasms, but good correlation between serum AFP levels and disease activity.
Serum CEA levels did not correlate with disease activity, and serial determinations
would therefore not be useful in monitoring progress in this group of diseases.
OF THE known oncofoetal antigens,
alpha-foetoprotein (AFP) and carcino-
embryonic antigen (CEA) have been the
most widely studied, and to date are con-
sidered to be of most value in clinical
practice. The presence of elevated levels
of serum AFP in some patients with germ
cell neoplasms has been noted during the
latter part ofthe last decade (Abelev et al.,
1967; Masopust et al., 1968; Mawas et al.,
1969) and, more recently, the association
between the increased AFP production in
patients with germ cell tumours composed
of, or containing, elements of endodermal
sinus tumour (yolk sac tumour) has been
demonstrated, both in human tumours
(Ballas, 1972; Tsuchida et al., 1973; Itoh
et al., 1974; Talerman and Haije, 1974;
N0rgaard-Petersen, Albrechtsen and Tei-
lum, 1975) and in experimental tumours in
mice (Hooghe et al., 1974). There have
been only a few reports on the value of
serum CEA determinations in patients
with germ cell neoplasms (Reynoso et al.,
1972; Wahren and Edsmyr, 1974).
PATIENTS AND METHODS
All patients with germ cell neoplasms of
the gonads and extragonadal sites attending
the Institute of Radiotherapy, and those
referred for diagnosis from other hospitals,
have had serum AFP and CEA determined.
Wheneverpossible, serial determinations have
been carried out, and this was the case in all
patients with evidence of active disease who
were either confined in hospital, or attended
at frequent intervals. Serial determinations
were less common in patients with no evi-
dence ofactive disease, and especially in those
surviving more than 2 years following
diagnosis, who were seen less frequently in
the follow-up clinic. All the histological
material available from these patients was
examined by one ofus (A.T.) either before, or
in conjunction with, the biochemical testing
and without any prior knowledge of the
results.
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Serum AFP.-All sera were screened by
counterimmunodiffusion using a slight modi-
fication of the method described by Alpert
et al. (1971). In cases where serum AFP was
more than 10,000 ng/ml, it was determined by
immunodiffusion using M-Partigen plates
(Behringwerke A.G.). In all other cases
except those with very high levels mentioned
above, serum AFP was determined by radio-
immunoassay, using the "a-feto RIA kit "
(Dianabot Radioisotope Lab., Ltd), the
normal range being 0-20 ng/ml.
Serum CEA.-The CEA was determined
by radioimmunoassay, using the method of
Hansen modified by Go et al. (1972), the
normal range being 0-2-5 ng/ml.
RESULTS
There were 70 patients under study,
comprising 65 patients with testicular
tumours, 4 patients with ovarian tumours,
and one patientwith a mediastinaltumour.
There were 15 patients with evidence
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ofactive disease, and 55 patients in remis-
sion lasting from 2 months to over 3 years.
All 5 patients with non-testicular tumours
and 10 patients with testicular tumours
had evidence of active disease.
The 5 patients with non-testicular
tumours comprised 4 withovariantumours
composed of endodermal sinus tumour
(yolk sac tumour) admixed with immature
and mature teratoma or embryonal carci-
noma in varying proportions, and one
patient with aprimarymediastinal tumour
composed entirely of endodermal sinus
tumour. All these patients had elevated
levels of serum AFP.
There was good correlation between
the amount of endodermal sinus tumour
elements within a tumour and the serum
AFP level, and 2 patients who had meta-
stases composed entirely of endodermal
sinus tumour (Figs 1 and 2)hadthehighest
levels of serum AFP.
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FIG. 1.-Serial serum AFP determinations in a 17-year-old female with bilateral ovarian tumours; a
large tumour composed of endodermal sinus tumour and mature and immature teratoma, and the
other a small mature teratoma. The first operation consisted of excision of both tumours, while
the second was a laparotomy and excision of numerous large tumour deposits composed entirely of
endodermal sinus tumour present in the abdominal cavity. The inset shows higher magnification
of serum AFP levels during the period when slight elevation of serum AFP became apparent;
clinically the patient was symptom-free. The period when serum AFP was within normal limits
(0.02 mg/l) is indicated by the broken arrow. The serum CEA determined at the same time was
below 2-5 ng/ml during the whole period under study.
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FIG. 2.-Serial serum AFP determinations, from the time ofdiagnosis till death, in a 28-year-old male
with primary mediastinal endodermal sinus tumour and liver metastases composed entirely of
endodermal sinus tumour elements. The serum CEA determined at the same time was below
2-5 ng/ml during the whole period under study.
All 5 patients with testicular tumours
containing endodermal sinus tumour
elements, and combined with malignant
teratoma of the intermediate and undif-
ferentiated types and/or seminoma, had
elevated levels of serum AFP. In these
cases there was also good correlation
between serum AFP levels and the
amount of endodermal sinus tumour
elements within a tumour. Higher serum
AFP levels were found when metastatic
tumour deposits were found on presenta-
tion. In all these cases, endodermal sinus
tumour elements formed a considerable
part ofthe tumour, although their amount
varied from case to case.
The range of serum AFP values in
patients with active disease on presenta-
tion varied from 1300 to 12,000 ng/ml and
there was good correlation with disease
activity when serial determinations were
performed. Very high levels of serum
AFP were encountered with progression of
the disease (Figs 1 and 2).
Ofthe 5 remaining patients with testi-
cular tumours, 4 had seminoma and one
had malignant teratoma undifferentiated
without endodermal sinus tumour ele-
ments. None of these patients had ele-
vated serum AFP.
The 55 patients withtesticular tumours
who were in remission comprised 29 pati-
ents with pure seminoma, 19 patients with
malignantteratomaoftheundifferentiated
and intermediate types, 6 patients with
combined tumours (seminoma and tera-
toma) and one patient with infantile endo-
dermal sinus tumour (yolk sac tumour).
None of the patients without evidence
of active disease had raised serum AFP.
None of 15 patients with active disease
was found to have raised serum CEA at
any time. In 54 patients without evi-
dence of active disease serum CEA was
found to be normal. Raised serum CEA
(16 ng/ml) was found only in one patient
with seminoma without any evidence of
active disease, and who has been in
remission for over 2 years. This patient
has now been followed up for another year,
and there is no evidence of recurrence, or
evidence of other disease process.
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Serum CEA was determined at the
same time in a number of patients with
carcinoma of the large intestine with
metastases. In all these patients there
was marked elevation of serum CEA.
DISCUSSION
The results of the present study show
that there is no correlation between serum
AFP and CEA levels in patients with germ
cell neoplasms.
They confirm the good correlation
between serum AFP levels and disease
activity, the value ofserial determinations
of serum AFP in monitoring the progress
of the disease and its response to therapy,
as well as the association between the
presence of endodermal sinus tumour
elements within the tumour and elevation
of serum AFP. In none of these cases
was there evidence ofdiscordance between
serum AFP levels and disease activity,
which is occasionally noted, especially
when choriocarcinomatous elements are
also present within the tumour (Braun-
stein, McIntyre and Waldmann, 1973;
Talerman and Haije, 1974; N0rgaard-
Petersen et al., 1975).
Although Reynoso et al. (1972) noted
raised serum CEA levels in 11 of 24
patients with testicular tumours, including
4/9 patients with seminoma, there was no
correlation between the elevation of
serum CEA and disease activity, and 50%
of patients with elevated serum CEA had
no evidence of active disease.
Transient elevation of serum CEA has
been noted in some patients withtesticular
teratoma, but not in patients with semi-
noma (Wahren and Edsmyr, 1974).
There was no correlation between serum
CEA levels and disease activity when
serum CEA was studied serially in these
patients, and it was considered that serum
CEA determinations are not suitable for
monitoring the progress of the disease
(Wahren and Edsmyr, 1974).
The results of the present study lend
further support to this view, and it is con-
sidered that serum CEA determinations
have no place in diagnosis or follow up of
patients with germ cell neoplasms.
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